
Supplemental Materials for manuscript “The First Ten Years of Highly Active Antiretroviral Therapy: a multi-regional Latin American cohort experience”

SIMULATED DATA: RESULTS ARE NOT TO BE INTERPRETED SUBSTANTIVELY, BUT ARE PROVIDED TO MAKE OUR STUDY QUASI-REPRODUCIBLE BY ALLOWING OTHERS TO VERIFY THE ANALYSIS CODE USED FOR THE ORIGINAL REPORT ON PUBLICLY AVAILABLE SIMULATED DATA.

(mock-ccasanet-data-2017-01-19)

SIMULATED DATA




Figure 1: Site-specific patient outcomes during the first 10 years of HAART among all patients who initiated HAART prior to 2004. Median (black line) as well as 25th percentile and 75th percentile CD4 (white lines) are also displayed. The percentage of active patients with a measured viral load and CD4 is given at the bottom of the figure.




Figure 2: Site-specific drug regimen status during the first ten years of HAART among all patients who initiated treatment prior to 2004. Patients were classified as lost to follow-up after their last documented visit date, regardless of the timing of the previous regimen dispensation.

Table 1: Demographic characteristics of patients who were active at one year and have a viral load measurement (n=1660).

	HF/CMH-Argentina n=796	INI-Brazil n=433	FA-Chile n=284	IHSS/HE-Honduras n=76	INCMNSZ-Mexico n=71	Combined n=1660
	Value	Value	Value	Value	Value	
Age, years	36 (30 - 42)	38 (31 - 44)	37 (30 - 42)	36 (31 - 42.25)	38 (30.5 - 45.5)	37 (30.75 - 43)
Sex						
Female	217(27%)	192(44%)	35(12%)	40(53%)	13(18%)	497(30%)
Male	579(73%)	241(56%)	249(88%)	36(47%)	58(82%)	1163(70%)
Probable Route of Infection						
Heterosexual	145(18%)	90(21%)	42(15%)	17(22%)	7(10%)	301(18%)
Homosexual or Bisexual	148(19%)	246(57%)	103(36%)	20(26%)	24(34%)	541(33%)
IDU	256(32%)	6(1%)	0(0%)	12(16%)	11(15%)	285(17%)
Other	116(15%)	40(9%)	1(0%)	17(22%)	28(39%)	202(12%)
Unknown	131(16%)	51(12%)	7(2%)	10(13%)	1(1%)	200(12%)
Clinical Stage						
AIDS	37(5%)	155(36%)	82(29%)	2(3%)	21(30%)	297(18%)
not AIDS	323(41%)	59(14%)	70(25%)	34(45%)	13(18%)	499(30%)
Missing	436(55%)	219(51%)	132(46%)	40(53%)	37(52%)	864(52%)
Nadir CD4, cells/mm ³	202 (99 - 336)	150 (69 - 265)	115 (44 - 236)	156 (62 - 235)	109 (47 - 183)	157 (70 - 284)
Missing	414(52%)	53(12%)	85(30%)	46(61%)	35(49%)	633(38%)
Baseline CD4, cells/mm ³	242 (134 - 386)	280 (142 - 393)	223 (118 - 402)	194 (103 - 243)	138 (86 - 220)	241 (129 - 378)
Missing	491(62%)	147(34%)	139(49%)	51(67%)	47(66%)	875(53%)
Baseline VL (log ₁₀)	4.5 (3.6 - 5.0)	4.2 (3.0 - 4.9)	4.4 (3.6 - 5.0)	4.1 (3.5 - 4.6)	4.4 (4.0 - 5.5)	4.3 (3.5 - 5.0)
Baseline VL (undetectable)						
Yes	40(5%)	64(15%)	12(4%)	3(4%)	3(4%)	122(7%)
No	265(33%)	222(51%)	133(47%)	22(29%)	21(30%)	663(40%)
Missing	491(62%)	147(34%)	139(49%)	51(67%)	47(66%)	875(53%)
Initial Regimen Class						
NNRTI	472(59%)	203(47%)	224(79%)	71(93%)	57(80%)	1027(62%)
Boosted PI	163(20%)	85(20%)	29(10%)	2(3%)	11(15%)	290(17%)
Unboosted PI	119(15%)	52(12%)	22(8%)	3(4%)	2(3%)	198(12%)
3 NRTI	29(4%)	0(0%)	2(1%)	0(0%)	0(0%)	31(2%)
Other	0(0%)	4(1%)	1(0%)	0(0%)	0(0%)	5(0%)
Missing	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Year of Initial Regimen						
1996	2(0%)	40(9%)	5(2%)	0(0%)	0(0%)	47(3%)
1997	3(0%)	47(11%)	10(4%)	0(0%)	0(0%)	60(4%)
1998	4(1%)	45(10%)	12(4%)	0(0%)	0(0%)	61(4%)
1999	19(2%)	44(10%)	21(7%)	0(0%)	0(0%)	84(5%)
2000	111(14%)	45(10%)	36(13%)	2(3%)	1(1%)	195(12%)
2001	211(27%)	63(15%)	57(20%)	2(3%)	7(10%)	340(20%)
2002	233(29%)	64(15%)	53(19%)	20(26%)	21(30%)	391(24%)
2003	213(27%)	85(20%)	90(32%)	52(68%)	42(59%)	482(29%)
ART naive						
Yes	386(48%)	282(65%)	248(87%)	74(97%)	70(99%)	1060(64%)
No	256(32%)	151(35%)	36(13%)	0(0%)	1(1%)	444(27%)
Unconfirmed	154(19%)	0(0%)	0(0%)	2(3%)	0(0%)	156(9%)

Table 2: Demographic characteristics of patients who were active at one year but did not have a viral load measurement (n=1364).

	HF/CMH-Argentina n=713	INI-Brazil n=345	FA-Chile n=197	IHSS/HE-Honduras n=64	INCMNSZ-Mexico n=45	Combined n=1364
	Value	Value	Value	Value	Value	
Age, years	37 (32 - 43)	36 (30 - 43)	36 (30 - 42)	34 (29 - 42)	36 (30 - 43)	37 (31 - 43)
Sex						
Female	165(23%)	147(43%)	30(15%)	25(39%)	6(13%)	373(27%)
Male	548(77%)	198(57%)	167(85%)	39(61%)	39(87%)	991(73%)
Probable Route of Infection						
Heterosexual	109(15%)	62(18%)	25(13%)	12(19%)	6(13%)	214(16%)
Homosexual or Bisexual	109(15%)	189(55%)	73(37%)	7(11%)	16(36%)	394(29%)
IDU	225(32%)	0(0%)	0(0%)	11(17%)	9(20%)	245(18%)
Other	123(17%)	45(13%)	0(0%)	21(33%)	13(29%)	202(15%)
Unknown	147(21%)	49(14%)	3(2%)	13(20%)	1(2%)	213(16%)
Clinical Stage						
AIDS	17(2%)	139(40%)	52(26%)	1(2%)	12(27%)	221(16%)
not AIDS	215(30%)	57(17%)	31(16%)	16(25%)	3(7%)	322(24%)
Missing	481(67%)	149(43%)	114(58%)	47(73%)	30(67%)	821(60%)
Nadir CD4, cells/mm ³	268 (131 - 388)	154 (77 - 288)	109 (50 - 214)	76 (38 - 190)	36 (17 - 53)	174 (79 - 332)
Missing	452(63%)	55(16%)	82(42%)	48(75%)	27(60%)	664(49%)
Baseline CD4, cells/mm ³	276 (134 - 429)	242 (128 - 377)	134 (65 - 261)	88 (46 - 138)	109 (48 - 175)	218 (110 - 385)
Missing	548(77%)	199(58%)	133(68%)	50(78%)	31(69%)	961(70%)
Baseline VL (log ₁₀)	4.7 (3.8 - 5.1)	4.5 (3.7 - 5.0)	4.5 (3.7 - 5.0)	4.6 (4.1 - 5.0)	4.9 (3.9 - 5.4)	4.6 (3.8 - 5.1)
Baseline VL (undetectable)						
Yes	10(1%)	24(7%)	6(3%)	0(0%)	1(2%)	41(3%)
No	155(22%)	122(35%)	58(29%)	14(22%)	13(29%)	362(27%)
Missing	548(77%)	199(58%)	133(68%)	50(78%)	31(69%)	961(70%)
Initial Regimen Class						
NNRTI	426(60%)	192(56%)	147(75%)	59(92%)	32(71%)	856(63%)
Boosted PI	144(20%)	69(20%)	19(10%)	4(6%)	9(20%)	245(18%)
Other	2(0%)	4(1%)	0(0%)	0(0%)	1(2%)	7(1%)
Missing	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Year of Initial Regimen						
1996	1(0%)	16(5%)	6(3%)	0(0%)	0(0%)	23(2%)
1997	5(1%)	24(7%)	2(1%)	0(0%)	0(0%)	31(2%)
1998	16(2%)	41(12%)	10(5%)	0(0%)	0(0%)	67(5%)
1999	60(8%)	28(8%)	22(11%)	1(2%)	0(0%)	111(8%)
2000	105(15%)	52(15%)	17(9%)	2(3%)	2(4%)	178(13%)
2001	170(24%)	66(19%)	47(24%)	12(19%)	4(9%)	299(22%)
2002	190(27%)	69(20%)	48(24%)	19(30%)	12(27%)	338(25%)
2003	166(23%)	49(14%)	45(23%)	30(47%)	27(60%)	317(23%)
ART naive						
Yes	358(50%)	240(70%)	166(84%)	62(97%)	45(100%)	871(64%)
No	200(28%)	105(30%)	31(16%)	0(0%)	0(0%)	336(25%)
Unconfirmed	155(22%)	0(0%)	0(0%)	2(3%)	0(0%)	157(12%)

Table 3: P-value comparison of demographic characteristics of patients who were active at one year and have a viral load measurement compared to those without a viral load measurement (n=3024). P-values for continuous variables were calculated using a Wilcoxon Rank Sum test. P-values for categorical variables were calculated using a Chi-squared test.

	HF/CMH-Argentina n=1509	INI-Brazil n=778	FA-Chile n=481	IHSS/HE-Honduras n=140	INCMNSZ-Mexico n=116	Combined n=3024
Age, years	0.090	0.199	0.737	0.301	0.525	0.993
Sex	0.075	0.681	0.435	0.152	0.654	0.127
Female						
Male						
Probable Route of Infection	0.048	0.058	0.783	0.136	0.805	0.003
Heterosexual						
Homosexual or Bisexual						
IDU						
Other						
Unknown						
Clinical Stage	0.284	0.818	0.250	1.000	0.355	0.233
AIDS						
not AIDS						
Missing						
Nadir CD4, cells/mm ³	< 0.001	0.251	0.520	0.239	0.008	0.019
Missing	< 0.001	0.168	0.011	0.102	0.350	< 0.001
Baseline CD4, cells/mm ³	0.091	0.211	0.005	0.077	0.215	0.225
Missing	< 0.001	< 0.001	< 0.001	0.208	0.922	< 0.001
Baseline VL (log ₁₀)	0.084	0.049	0.621	0.089	0.856	0.003
Baseline VL (undetectable)	0.027	0.186	1.000	0.470	1.000	0.014
Yes						
No						
Missing						
Initial Regimen Class	0.791	0.057	0.489	0.415	0.436	0.453
NNRTI						
Boosted PI						
Other						
Missing						
Year of Initial Regimen	< 0.001	0.002	0.064	0.011	0.778	< 0.001
1996						
1997						
1998						
1999						
2000						
2001						
2002						
2003						
ART naive	0.185	0.218	0.413	1.000	1.000	0.104
Yes						
No						
Unconfirmed						

Table 4: Demographic characteristics of ART-naive patients initiating HAART in the CCASAnet cohort (n=2889).

	HF/CMH-Argentina n=899	INI-Brazil n=602	FA-Chile n=562	GHEKIO-Haiti n=551	IHSS/HE-Honduras n=151	INCMNSZ-Mexico n=124	Combined n=2889
	Value	Value	Value	Value	Value	Value	
Age, years	36 (31 - 42)	37 (30 - 43)	37.5 (31 - 44)	39 (33 - 45)	35 (30 - 42)	37 (30 - 44.25)	37 (31 - 44)
Sex							
Female	213(24%)	265(44%)	70(12%)	300(54%)	65(43%)	20(16%)	933(32%)
Male	686(76%)	337(56%)	492(88%)	251(46%)	86(57%)	104(84%)	1956(68%)
Probable Route of Infection							
Heterosexual	154(17%)	115(19%)	71(13%)	0(0%)	30(20%)	15(12%)	385(13%)
Homosexual or Bisexual	154(17%)	339(56%)	182(32%)	0(0%)	26(17%)	43(35%)	744(26%)
IDU	290(32%)	3(0%)	0(0%)	0(0%)	26(17%)	21(17%)	340(12%)
Other	125(14%)	65(11%)	1(0%)	0(0%)	43(28%)	43(35%)	277(10%)
Unknown	176(20%)	80(13%)	11(2%)	551(100%)	26(17%)	2(2%)	846(29%)
Clinical Stage							
AIDS	31(3%)	224(37%)	142(25%)	45(8%)	3(2%)	34(27%)	479(17%)
not AIDS	336(37%)	86(14%)	126(22%)	143(26%)	57(38%)	18(15%)	766(27%)
Missing	532(59%)	292(49%)	294(52%)	363(66%)	91(60%)	72(58%)	1644(57%)
Nadir CD4, cells/mm ³	214 (100 - 354)	153 (75 - 278)	120 (41 - 244)	107 (36 - 197)	112 (44 - 232)	72 (23 - 138)	148 (61 - 274)
Missing	547(61%)	121(20%)	252(45%)	339(62%)	102(68%)	67(54%)	1428(49%)
Baseline CD4, cells/mm ³	242 (122 - 387)	234 (120 - 347)	185 (97 - 363)	160 (50 - 238)	148 (53 - 240)	133 (78 - 215)	200 (98 - 337)
Missing	632(70%)	306(51%)	369(66%)	376(68%)	110(73%)	86(69%)	1879(65%)
Baseline VL (log ₁₀)	4.6 (3.8 - 5.1)	4.5 (3.9 - 5.0)	4.4 (3.7 - 5.0)	NA (NA - NA)	4.3 (3.6 - 4.9)	4.7 (3.9 - 5.4)	4.5 (3.8 - 5.0)
Baseline VL (undetectable)							
Yes	24(3%)	21(3%)	16(3%)	0(0%)	3(2%)	3(2%)	67(2%)
No	243(27%)	275(46%)	177(31%)	0(0%)	38(25%)	35(28%)	768(27%)
Missing	632(70%)	306(51%)	369(66%)	551(100%)	110(73%)	86(69%)	2054(71%)
Initial Regimen Class							
NNRTI	547(61%)	371(62%)	441(78%)	521(95%)	139(92%)	97(78%)	2116(73%)
Boosted PI	172(19%)	150(25%)	63(11%)	23(4%)	7(5%)	21(17%)	436(15%)
Unboosted PI	140(16%)	74(12%)	50(9%)	1(0%)	5(3%)	5(4%)	275(10%)
3 NRTI	38(4%)	0(0%)	6(1%)	6(1%)	0(0%)	0(0%)	50(2%)
Other	2(0%)	7(1%)	2(0%)	0(0%)	0(0%)	1(1%)	12(0%)
Missing	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Year of Initial Regimen							
1996	5(1%)	46(8%)	15(3%)	0(0%)	0(0%)	0(0%)	66(2%)
1997	8(1%)	60(10%)	23(4%)	0(0%)	0(0%)	0(0%)	91(3%)
1998	10(1%)	64(11%)	34(6%)	0(0%)	0(0%)	0(0%)	108(4%)
1999	46(5%)	60(10%)	49(9%)	0(0%)	0(0%)	0(0%)	155(5%)
2000	125(14%)	73(12%)	65(12%)	4(1%)	4(3%)	3(2%)	274(9%)
2001	243(27%)	94(16%)	112(20%)	16(3%)	14(9%)	11(9%)	490(17%)
2002	251(28%)	101(17%)	113(20%)	115(21%)	45(30%)	37(30%)	662(23%)
2003	211(23%)	104(17%)	151(27%)	416(75%)	88(58%)	73(59%)	1043(36%)
ART naive							
Yes	899(100%)	602(100%)	562(100%)	551(100%)	151(100%)	124(100%)	2889(100%)
No	(%)	(%)	(%)	(%)	(%)	(%)	(%)
Unconfirmed	(%)	(%)	(%)	(%)	(%)	(%)	(%)

Table 5: Demographic characteristics of ART experienced patients initiating HAART in the CCASAnet cohort (n=972).

	HF/CMH-Argentina n=542	INI-Brazil n=283	FA-Chile n=76	GHEKIO-Haiti n=70	IHSS/HE-Honduras n=0	INCMNSZ-Mexico n=1	Combined n=972
	Value	Value	Value	Value	Value	Value	
Age, years	37 (31 - 43)	37 (30 - 44)	37 (30.75 - 44.25)	38.5 (32.25 - 43)	N/A (N/A - N/A)	44 (44 - 44)	37 (31 - 43)
Sex							
Female	144(27%)	113(40%)	12(16%)	37(53%)	0(NaN%)	0(0%)	306(31%)
Male	398(73%)	170(60%)	64(84%)	33(47%)	0(NaN%)	1(100%)	666(69%)
Probable Route of Infection							
Heterosexual	79(15%)	58(20%)	10(13%)	0(0%)	0(NaN%)	0(0%)	147(15%)
Homosexual or Bisexual	101(19%)	159(56%)	28(37%)	0(0%)	0(NaN%)	0(0%)	288(30%)
IDU	182(34%)	4(1%)	0(0%)	0(0%)	0(NaN%)	0(0%)	186(19%)
Other	83(15%)	30(11%)	0(0%)	0(0%)	0(NaN%)	1(100%)	114(12%)
Unknown	97(18%)	32(11%)	3(4%)	70(100%)	0(NaN%)	0(0%)	202(21%)
Clinical Stage							
AIDS	19(4%)	104(37%)	23(30%)	5(7%)	0(NaN%)	0(0%)	151(16%)
not AIDS	199(37%)	42(15%)	15(20%)	21(30%)	0(NaN%)	0(0%)	277(28%)
Missing	324(60%)	137(48%)	38(50%)	44(63%)	0(NaN%)	1(100%)	544(56%)
Nadir CD4, cells/mm ³	218 (104 - 372)	162 (74 - 292)	115 (61 - 212)	101 (48 - 164)	NA (NA - NA)	248 (248 - 248)	166 (79 - 304)
Missing	323(60%)	39(14%)	26(34%)	43(61%)	0(NaN%)	0(0%)	431(44%)
Baseline CD4, cells/mm ³	247 (122 - 398)	318 (194 - 465)	211 (121 - 266)	135 (61 - 160)	NA (NA - NA)	248 (248 - 248)	256 (134 - 412)
Missing	394(73%)	132(47%)	39(51%)	51(73%)	0(NaN%)	0(0%)	616(63%)
Baseline VL (log ₁₀)	4.4 (3.7 - 5.0)	3.2 (1.7 - 4.5)	4.4 (3.3 - 4.8)	NA (NA - NA)	NA (NA - NA)	1.9 (1.9 - 1.9)	4.0 (2.3 - 4.8)
Baseline VL (undetectable)							
Yes	21(4%)	69(24%)	7(9%)	0(0%)	0(NaN%)	1(100%)	98(10%)
No	127(23%)	82(29%)	30(39%)	0(0%)	0(NaN%)	0(0%)	239(25%)
Missing	394(73%)	132(47%)	39(51%)	70(100%)	0(NaN%)	0(0%)	635(65%)
Initial Regimen Class							
NNRTI	311(57%)	87(31%)	48(63%)	64(91%)	0(NaN%)	0(0%)	510(52%)
Boosted PI	117(22%)	38(13%)	2(3%)	3(4%)	0(NaN%)	0(0%)	160(16%)
Unboosted PI	68(13%)	13(5%)	10(13%)	2(3%)	0(NaN%)	0(0%)	93(10%)
3 NRTI	19(4%)	1(0%)	0(0%)	0(0%)	0(NaN%)	0(0%)	20(2%)
Other	0(0%)	3(1%)	0(0%)	0(0%)	0(NaN%)	0(0%)	3(0%)
Missing	0(0%)	0(0%)	0(0%)	0(0%)	0(NaN%)	0(0%)	0(0%)
Year of Initial Regimen							
1996	3(1%)	29(10%)	1(1%)	0(0%)	0(NaN%)	0(0%)	33(3%)
1997	4(1%)	24(8%)	3(4%)	0(0%)	0(NaN%)	0(0%)	31(3%)
1998	13(2%)	32(11%)	3(4%)	0(0%)	0(NaN%)	0(0%)	48(5%)
1999	28(5%)	25(9%)	10(13%)	0(0%)	0(NaN%)	0(0%)	63(6%)
2000	92(17%)	36(13%)	7(9%)	0(0%)	0(NaN%)	0(0%)	135(14%)
2001	142(26%)	46(16%)	19(25%)	2(3%)	0(NaN%)	0(0%)	209(22%)
2002	129(24%)	41(14%)	13(17%)	11(16%)	0(NaN%)	0(0%)	194(20%)
2003	131(24%)	50(18%)	20(26%)	57(81%)	0(NaN%)	1(100%)	259(27%)
ART naive							
Yes	(%)	(%)	(%)	(%)	(%)	(%)	(%)
No	542(100%)	283(100%)	76(100%)	70(100%)	0(NaN%)	1(100%)	972(100%)
Unconfirmed	(%)	(%)	(%)	(%)	(%)	(%)	(%)

Table 6: P-value comparison of demographic characteristics of patients who were ART-naive at HAART initiation with those who were not (n=3861). P-values for continuous variables were calculated using a Wilcoxon Rank Sum test. P-values for categorical variables were calculated using a Chi-squared test.

	HF/CMH-Argentina n=1441	INI-Brazil n=885	FA-Chile n=638	IHSS/HE-Honduras n=151	INCMNSZ-Mexico n=125	Combined n=3861
Age, years	0.412	0.906	0.686	N A	0.429	0.649
Sex	0.245	0.283	0.527	N A	1.000	0.667
Female						
Male						
Probable Route of Infection	0.567	0.586	0.671	N A	0.762	< 0.001
Heterosexual						
Homosexual or Bisexual						
IDU						
Other						
Unknown						
Clinical Stage	1.000	0.908	0.485	N A	N A	0.263
AIDS						
not AIDS						
Missing						
Nadir CD4, cells/mm ³	0.929	0.971	1.000	N A	0.169	0.004
Missing	0.678	0.029	0.103	N A	0.942	0.007
Baseline CD4, cells/mm ³	0.688	< 0.001	0.839	N A	0.267	< 0.001
Missing	0.362	0.276	0.021	N A	0.684	0.368
Baseline VL (log ₁₀)	0.130	< 0.001	0.202	N A	0.155	< 0.001
Baseline VL (undetectable)	0.142	< 0.001	0.094	N A	0.184	< 0.001
Yes						
No						
Missing						
Initial Regimen Class	< 0.001	< 0.001	< 0.001	N A	< 0.001	< 0.001
NNRTI						
Boosted PI						
Unboosted PI						
3 NRTI						
Other						
Missing						
Year of Initial Regimen	0.328	0.877	0.790	N A	0.874	< 0.001
1996						
1997						
1998						
1999						
2000						
2001						
2002						
2003						
ART naive	N A	N A	N A	N A	N A	N A
Yes						
No						
Unconfirmed						




Figure 3: Site-specific patient outcomes during the first 10 years of HAART among all ART-naïve patients who initiated HAART prior to 2004. Median (black line) as well as 25th percentile and 75th percentile CD4 (white lines) are also displayed. The percentage of active patients with a measured viral load and CD4 is given at the bottom of the figure.




Figure 4: Site-specific drug regimen status during the first ten years of HAART among ART-naïve patients who initiated treatment prior to 2004. Patients were classified as lost to follow-up after their last documented visit date, regardless of the timing of the previous regimen dispensation.

Table 7: Entire cohort patient status over time – all sites (n=4975)

Year	Dead	LTFU	000-400	401-1000	1001-Inf	Median CD4 cell count	VL \leq 400 among active patients
0.5	3.0%	1.4%	63.1%	5.7%	26.8%	252 (147 - 404)	66.0%
1	4.2%	2.4%	60.1%	4.2%	29.1%	288 (178 - 438)	64.4%
3	6.8%	6.4%	59.5%	3.5%	23.7%	381 (239 - 554)	68.6%
5	9.0%	10.9%	57.4%	3.1%	19.7%	423 (276 - 614)	71.6%
7	10.8%	14.8%	58.5%	1.9%	14.0%	476 (309 - 678)	78.7%
10	13.6%	24.2%	52.5%	1.5%	8.3%	525 (337 - 743)	84.4%

Table 8: Naive cohort patient status over time – all sites (n=2727)

Year	Dead	LTFU	000-400	401-1000	1001-Inf	Median CD4 cell count	VL \leq 400 among active patients
0.5	4.8%	2.2%	76.2%	4.9%	11.9%	232 (142 - 356)	82.0%
1	6.3%	3.7%	70.2%	3.2%	16.6%	271 (179 - 402)	78.0%
3	9.3%	8.9%	66.9%	1.7%	13.2%	385 (255 - 530)	81.8%
5	11.3%	14.9%	62.6%	2.0%	9.2%	432 (305 - 611)	84.8%
7	12.9%	18.8%	59.8%	1.3%	7.3%	497 (341 - 700)	87.5%
10	15.3%	28.6%	51.1%	0.8%	4.3%	554 (383 - 772)	91.0%

Table 9: Treatment experienced cohort patient status over time – all sites (n=2248)

Year	Dead	LTFU	000-400	401-1000	1001-Inf	Median CD4 cell count	VL \leq 400 among active patients
0.5	0.8%	0.4%	51.0%	6.6%	41.3%	287 (151 - 449)	51.6%
1	1.6%	0.8%	51.0%	5.2%	41.4%	318 (172 - 473)	52.3%
3	3.7%	3.3%	53.2%	5.3%	34.4%	377 (219 - 571)	57.3%
5	6.1%	6.0%	53.2%	4.2%	30.4%	412 (249 - 614)	60.6%
7	8.2%	10.0%	58.4%	2.5%	20.8%	449 (274 - 664)	71.4%
10	11.6%	19.0%	55.0%	2.2%	12.3%	494 (291 - 722)	79.1%

Table 10: Entire cohort drug frequencies – all sites (n=4975)

Year	Regimen 1	Regimen 2	Regimen 3	Regimen 4+	Interruption	LTFU	Dead
0	4975 (100%)	0	0	0	0	0	0
0.5	3732(75.0%)	639(12.8%)	143(2.9%)	30(0.6%)	214(4.3%)	69(1.4%)	148(3.0%)
1	3138(63.1%)	899(18.1%)	273(5.5%)	81(1.6%)	257(5.2%)	118(2.4%)	209(4.2%)
3	1983(39.9%)	1056(21.2%)	553(11.1%)	395(7.9%)	331(6.7%)	319(6.4%)	338(6.8%)
5	1352(27.2%)	970(19.5%)	638(12.8%)	688(13.8%)	338(6.8%)	542(10.9%)	447(9.0%)
7	960(19.3%)	872(17.5%)	620(12.5%)	949(19.1%)	299(6.0%)	739(14.9%)	536(10.8%)
10	569(11.4%)	628(12.6%)	574(11.5%)	1146(23.0%)	176(3.5%)	1206(24.2%)	676(13.6%)

Table 11: Naive cohort drug frequencies – all sites (n=2727)

Year	Regimen 1	Regimen 2	Regimen 3	Regimen 4+	Interruption	LTFU	Dead
0	2727 (100%)	0	0	0	0	0	0
0.5	1979(72.6%)	356(13.1%)	81(3.0%)	19(0.7%)	101(3.7%)	61(2.2%)	130(4.8%)
1	1711(62.7%)	465(17.1%)	129(4.7%)	36(1.3%)	113(4.1%)	100(3.7%)	173(6.3%)
3	1179(43.2%)	532(19.5%)	244(8.9%)	145(5.3%)	129(4.7%)	244(8.9%)	254(9.3%)
5	874(32.0%)	507(18.6%)	276(10.1%)	240(8.8%)	115(4.2%)	406(14.9%)	309(11.3%)
7	677(24.8%)	459(16.8%)	314(11.5%)	323(11.8%)	89(3.3%)	514(18.8%)	351(12.9%)
10	438(16.1%)	338(12.4%)	292(10.7%)	404(14.8%)	59(2.2%)	780(28.6%)	416(15.3%)

Table 12: Treatment experienced cohort drug frequencies – all sites (n=2248)

Year	Regimen 1	Regimen 2	Regimen 3	Regimen 4+	Interruption	LTFU	Dead
0	2248 (100%)	0	0	0	0	0	0
0.5	1753(78.0%)	283(12.6%)	62(2.8%)	11(0.5%)	113(5.0%)	8(0.4%)	18(0.8%)
1	1427(63.5%)	434(19.3%)	144(6.4%)	45(2.0%)	144(6.4%)	18(0.8%)	36(1.6%)
3	804(35.8%)	524(23.3%)	309(13.7%)	250(11.1%)	202(9.0%)	75(3.3%)	84(3.7%)
5	478(21.3%)	463(20.6%)	362(16.1%)	448(19.9%)	223(9.9%)	136(6.0%)	138(6.1%)
7	283(12.6%)	413(18.4%)	306(13.6%)	626(27.8%)	210(9.3%)	225(10.0%)	185(8.2%)
10	131(5.8%)	290(12.9%)	282(12.5%)	742(33.0%)	117(5.2%)	426(19.0%)	260(11.6%)

Table 13: Entire cohort patient status over time – Argentina (n=1724)

Year	Dead	LTFU	000-400	401-1000	1001-Inf	Median CD4 cell count	VL \leq 400 among active patients
0.5	0.7%	2.7%	66.6%	6.7%	23.3%	290 (155 - 461)	68.9%
1	1.1%	4.3%	66.4%	5.4%	22.8%	314 (188 - 467)	70.2%
3	1.5%	12.2%	64.7%	3.5%	18.2%	414 (261 - 585)	74.9%
5	2.1%	20.3%	59.6%	2.9%	15.1%	449 (302 - 637)	76.8%
7	2.4%	27.6%	56.4%	2.1%	11.5%	475 (317 - 659)	80.5%
10	3.5%	44.4%	44.5%	1.1%	6.5%	502 (330 - 704)	85.4%

Table 14: Entire cohort drug frequencies – Argentina (n=1724)

Year	Regimen 1	Regimen 2	Regimen 3	Regimen 4+	Interruption	LTFU	Dead
0	1724 (100%)	0	0	0	0	0	0
0.5	1353(78.5%)	158(9.2%)	28(1.6%)	4(0.2%)	122(7.1%)	47(2.7%)	12(0.7%)
1	1159(67.2%)	251(14.6%)	62(3.6%)	8(0.5%)	151(8.8%)	74(4.3%)	19(1.1%)
3	680(39.4%)	357(20.7%)	156(9.0%)	89(5.2%)	206(11.9%)	210(12.2%)	26(1.5%)
5	413(24.0%)	334(19.4%)	212(12.3%)	177(10.3%)	201(11.7%)	350(20.3%)	37(2.1%)
7	262(15.2%)	315(18.3%)	183(10.6%)	263(15.3%)	184(10.7%)	476(27.6%)	41(2.4%)
10	115(6.7%)	234(13.6%)	162(9.4%)	296(17.2%)	92(5.3%)	765(44.4%)	60(3.5%)

Table 15: Entire cohort patient status over time – Brazil (n=1374)

Year	Dead	LTFU	000-400	401-1000	1001-Inf	Median CD4 cell count	VL \leq 400 among active patients
0.5	2.1%	0.1%	46.5%	7.0%	44.3%	276 (168 - 436)	47.6%
1	3.7%	0.4%	43.7%	3.6%	48.6%	306 (180 - 468)	45.5%
3	7.9%	1.2%	47.6%	3.9%	39.4%	378 (223 - 582)	52.4%
5	12.4%	1.9%	46.8%	4.1%	34.7%	407 (235 - 622)	54.6%
7	16.2%	2.3%	55.0%	2.1%	24.4%	471 (273 - 706)	67.5%
10	21.6%	4.9%	57.5%	2.3%	13.6%	530 (299 - 803)	78.3%

Table 16: Entire cohort drug frequencies – Brazil (n=1374)

Year	Regimen 1	Regimen 2	Regimen 3	Regimen 4+	Interruption	LTFU	Dead
0	1374 (100%)	0	0	0	0	0	0
0.5	1009(73.4%)	224(16.3%)	44(3.2%)	11(0.8%)	55(4.0%)	2(0.1%)	29(2.1%)
1	783(57.0%)	323(23.5%)	103(7.5%)	42(3.1%)	67(4.9%)	5(0.4%)	51(3.7%)
3	417(30.3%)	320(23.3%)	207(15.1%)	228(16.6%)	77(5.6%)	16(1.2%)	109(7.9%)
5	282(20.5%)	251(18.3%)	197(14.3%)	362(26.3%)	85(6.2%)	26(1.9%)	171(12.4%)
7	181(13.2%)	215(15.6%)	189(13.8%)	473(34.4%)	62(4.5%)	31(2.3%)	223(16.2%)
10	102(7.4%)	139(10.1%)	166(12.1%)	563(41.0%)	39(2.8%)	68(4.9%)	297(21.6%)

Table 17: Entire cohort patient status over time – Chile (n=701)

Year	Dead	LTFU	000-400	401-1000	1001-Inf	Median CD4 cell count	VL \leq 400 among active patients
0.5	1.7%	0.4%	79.3%	3.9%	14.7%	168 (99 - 287)	81.0%
1	2.9%	0.7%	77.0%	4.6%	14.8%	206 (128 - 340)	79.9%
3	4.1%	1.7%	75.7%	4.9%	13.6%	319 (197 - 462)	80.5%
5	5.3%	2.6%	76.9%	3.4%	11.8%	382 (246 - 560)	83.4%
7	7.4%	4.3%	79.3%	1.7%	7.3%	468 (314 - 656)	89.8%
10	10.8%	8.6%	72.0%	1.6%	7.0%	512 (368 - 715)	89.4%

Table 18: Entire cohort drug frequencies – Chile (n=701)

Year	Regimen 1	Regimen 2	Regimen 3	Regimen 4+	Interruption	LTFU	Dead
0	701 (100%)	0	0	0	0	0	0
0.5	541(77.2%)	94(13.4%)	15(2.1%)	3(0.4%)	33(4.7%)	3(0.4%)	12(1.7%)
1	465(66.3%)	142(20.3%)	25(3.6%)	8(1.1%)	36(5.1%)	5(0.7%)	20(2.9%)
3	318(45.4%)	186(26.5%)	76(10.8%)	41(5.8%)	39(5.6%)	12(1.7%)	29(4.1%)
5	226(32.2%)	182(26.0%)	108(15.4%)	85(12.1%)	45(6.4%)	18(2.6%)	37(5.3%)
7	167(23.8%)	167(23.8%)	121(17.3%)	120(17.1%)	44(6.3%)	30(4.3%)	52(7.4%)
10	107(15.3%)	133(19.0%)	120(17.1%)	164(23.4%)	41(5.8%)	60(8.6%)	76(10.8%)

Table 19: Entire cohort patient status over time – Haiti (n=803)

Year	Dead	LTFU	000-400	401-1000	1001-Inf	Median CD4 cell count	VL \leq 400 among active patients
0.5	10.0%	2.1%	NA%	NA%	NA%	256 (164 - 364)	81.0%
1	12.3%	3.4%	NA%	NA%	NA%	300 (211 - 420)	79.9%
3	17.8%	7.5%	NA%	NA%	NA%	388 (283 - 520)	80.5%
5	20.8%	13.7%	NA%	NA%	NA%	450 (329 - 617)	83.4%
7	21.9%	18.9%	NA%	NA%	NA%	539 (384 - 715)	89.8%
10	23.3%	27.3%	NA%	NA%	NA%	631 (432 - 836)	89.4%

Table 20: Entire cohort drug frequencies – Haiti (n=803)

Year	Regimen 1	Regimen 2	Regimen 3	Regimen 4+	Interruption	LTFU	Dead
0	803 (100%)	0	0	0	0	0	0
0.5	518(64.5%)	121(15.1%)	54(6.7%)	12(1.5%)	1(0.1%)	17(2.1%)	80(10.0%)
1	454(56.5%)	122(15.2%)	77(9.6%)	23(2.9%)	1(0.1%)	27(3.4%)	99(12.3%)
3	364(45.3%)	123(15.3%)	82(10.2%)	31(3.9%)	0(0.0%)	60(7.5%)	143(17.8%)
5	292(36.4%)	121(15.1%)	77(9.6%)	36(4.5%)	0(0.0%)	110(13.7%)	167(20.8%)
7	244(30.4%)	103(12.8%)	72(9.0%)	55(6.8%)	1(0.1%)	152(18.9%)	176(21.9%)
10	183(22.8%)	84(10.5%)	62(7.7%)	67(8.3%)	1(0.1%)	219(27.3%)	187(23.3%)

Table 21: Entire cohort patient status over time – Honduras (n=220)

Year	Dead	LTFU	000-400	401-1000	1001-Inf	Median CD4 cell count	VL \leq 400 among active patients
0.5	5.5%	NA%	89.1%	NA%	5.5%	232 (164 - 332)	89.1%
1	7.3%	0.9%	66.8%	NA%	25.0%	275 (196 - 388)	67.4%
3	11.4%	2.7%	60.9%	NA%	25.0%	340 (235 - 425)	62.6%
5	12.3%	7.3%	70.9%	NA%	9.5%	350 (258 - 450)	76.5%
7	15.5%	10.0%	66.4%	1.8%	6.4%	400 (290 - 555)	89.0%
10	19.5%	23.6%	53.6%	NA%	3.2%	440 (325 - 575)	70.2%

Table 22: Entire cohort drug frequencies – Honduras (n=220)

Year	Regimen 1	Regimen 2	Regimen 3	Regimen 4+	Interruption	LTFU	Dead
0	220 (100%)	0	0	0	0	0	0
0.5	184(83.6%)	21(9.5%)	0(0.0%)	0(0.0%)	3(1.4%)	0(0.0%)	12(5.5%)
1	167(75.9%)	33(15.0%)	2(0.9%)	0(0.0%)	0(0.0%)	2(0.9%)	16(7.3%)
3	129(58.6%)	36(16.4%)	15(6.8%)	2(0.9%)	7(3.2%)	6(2.7%)	25(11.4%)
5	106(48.2%)	36(16.4%)	16(7.3%)	13(5.9%)	6(2.7%)	16(7.3%)	27(12.3%)
7	92(41.8%)	27(12.3%)	24(10.9%)	16(7.3%)	5(2.3%)	22(10.0%)	34(15.5%)
10	56(25.5%)	26(11.8%)	18(8.2%)	23(10.5%)	2(0.9%)	52(23.6%)	43(19.5%)

Table 23: Entire cohort patient status over time – Mexico (n=153)

Year	Dead	LTFU	000-400	401-1000	1001-Inf	Median CD4 cell count	VL \leq 400 among active patients
0.5	2.0%	NA%	88.2%	2.6%	7.2%	196 (118 - 324)	90.0%
1	2.6%	3.3%	81.0%	2.6%	10.5%	257 (166 - 376)	86.1%
3	3.9%	9.8%	75.8%	2.0%	8.5%	406 (257 - 576)	87.9%
5	5.2%	14.4%	73.2%	1.3%	5.9%	427 (282 - 646)	91.1%
7	6.5%	18.3%	70.6%	NA%	4.6%	459 (291 - 660)	86.4%
10	8.5%	27.5%	61.4%	0.7%	2.0%	568 (427 - 766)	95.9%

Table 24: Entire cohort drug frequencies – Mexico (n=153)

Year	Regimen 1	Regimen 2	Regimen 3	Regimen 4+	Interruption	LTFU	Dead
0	153 (100%)	0	0	0	0	0	0
0.5	127(83.0%)	21(13.7%)	2(1.3%)	0(0.0%)	0(0.0%)	0(0.0%)	3(2.0%)
1	110(71.9%)	28(18.3%)	4(2.6%)	0(0.0%)	2(1.3%)	5(3.3%)	4(2.6%)
3	75(49.0%)	34(22.2%)	17(11.1%)	4(2.6%)	2(1.3%)	15(9.8%)	6(3.9%)
5	33(21.6%)	46(30.1%)	28(18.3%)	15(9.8%)	1(0.7%)	22(14.4%)	8(5.2%)
7	14(9.2%)	45(29.4%)	31(20.3%)	22(14.4%)	3(2.0%)	28(18.3%)	10(6.5%)
10	6(3.9%)	12(7.8%)	46(30.1%)	33(21.6%)	1(0.7%)	42(27.5%)	13(8.5%)